Product Information

WIXELA 500-50 INHUB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.6494 per EA under NDC 00378932232. Its NADAC has been published 384 times since Apr 17, 2019.

FDA first approved this application on Jan 30, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

WIXELA 500-50 INHUB

fluticasone propionate and salmeterol
$1.6494per EA

Strength

500; 50 ug/1; ug/1

NDC

00378932232

Classification

Generic

Dosage Form

POWDER

Route

RESPIRATORY (INHALATION)

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA208891

FDA Approved

1/30/2019

TE Code

AB

On Market Since

2/11/2019

Pharmacological Classes

Adrenergic beta2-Agonists
Corticosteroid Hormone Receptor Agonists
Corticosteroid
beta2-Adrenergic Agonist

Price Statistics

The NADAC for WIXELA 500-50 INHUB has been published 384 times since Apr 17, 2019, and over the history we have for it it has declined 68.3%. The table below summarizes its recorded NADAC range and movement.

Current price$1.6494 per EA
All-time high$5.2104 (May 15, 2019)
All-time low$1.4573 (Jul 17, 2024)
52-week high$1.7934
52-week low$1.6120
Median price$2.9630
Average price$2.7670
Largest weekly change+44.0% (Aug 21, 2024)
Weeks tracked384
Tracking sinceApr 17, 2019

Price History

1W

+2.0%

1M

+2.0%

3M

+0.5%

6M

-3.3%

1Y

-8.0%

3Y

-43.2%

5Y

-50.4%

All

-68.3%

Generic Alternatives

The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of WIXELA 500-50 INHUB?

The current National Average Drug Acquisition Cost (NADAC) for WIXELA 500-50 INHUB, manufactured by Mylan Pharmaceuticals Inc., is $1.6494 per EA (NDC 00378932232), effective Aug 19, 2026.

How has the price of WIXELA 500-50 INHUB changed over time?

Over the history we have for it, the NADAC for WIXELA 500-50 INHUB has declined 68.3%. It has been tracked across 384 weekly CMS publications since Apr 17, 2019.

What are the highest and lowest recorded NADAC prices for WIXELA 500-50 INHUB?

Since Apr 17, 2019, the NADAC for WIXELA 500-50 INHUB has ranged from a low of $1.4573 (Jul 17, 2024) to a high of $5.2104 (May 15, 2019), with a median of $2.9630 per EA.

Are there cheaper alternatives to WIXELA 500-50 INHUB?

4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as WIXELA 500-50 INHUB in a comparable dosage form, but none are currently priced below it.

Who manufactures WIXELA 500-50 INHUB?

WIXELA 500-50 INHUB (NDC 00378932232) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.